KemPharm announced an addition to its senior leadership team with the promotion of Dr. Andrew Barrett as Vice President, Scientific Affairs. Barrett has contributed to KemPharm’s scientific research and development since early 2016, playing a role in the clinical/regulatory development of KemPharm’s pipeline assets and communicating key scientific findings to the medical and investor communities.
As Vice President, Scientific Affairs, Barrett will be responsible for leading KemPharm’s medical communications strategies, while continuing to contribute to clinical/regulatory efforts. Prior to joining KemPharm, Barrett held positions of increasing responsibility at Chimerix, Salix, Synchrony Healthcare, and Cephalon. He earned his Ph.D. in Neuroscience at University of North Carolina at Chapel Hill, and completed postdoctoral training at Harvard Medical School/McLean Hospital where he studied the abuse-related effects of stimulants and opioids.
“We are pleased to announce Andy’s formal promotion to KemPharm’s leadership team,” Travis Mickle, Ph.D., KemPharm’s President and Chief Executive Officer said. “Andy has been a key contributor and an invaluable resource to KemPharm since he joined us. This elevation further strengthens the management team at an important stage in our business evolution as we continue the development of our portfolio of prodrug product candidates and seek new opportunities to leverage our Ligand Activated Therapy (LAT) prodrug platform.”